Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Previous attempts to treat human malignancies by adoptive transfer of tumor-specific CTLs have been limited by the difficulty of isolating T cells of defined antigen specificity. The recent development of MHC class I/antigenic peptide tetrameric complexes that allow direct identification of antigen-specific T cells has opened new possibilities for the isolation and in vitro expansion of tumor-specific T cells. In the present study, we have derived polyclonal monospecific cell lines from circulating Melan-A-specific CTL precursors of HLA-A*0201+ melanoma patients by combining stimulation with recently identified peptide analogues of the immunodominant epitope from the melanoma-associated antigen Melan-A with staining with fluorescent HLA-A*0201/Melan-A peptide tetramers. In vitro expansion of antigen-specific CD8+ T cells was monitored by flow cytometry with the fluorescent tetramers and anti-CD8 monoclonal antibody. This analysis revealed that Melan-A 26-35 peptide analogues were much more efficient than the parental peptides in stimulating a rapid in vitro expansion of antigen-specific CD8+ T cells. These cells were then isolated by tetramer-guided cell sorting and subsequently expanded in vitro by mitogen stimulation. The resulting polyclonal but monospecific CTLs fully cross-recognized the parental peptides and were able to efficiently lyse Melan-A-expressing tumor cells. Altogether, these results pave the way to a molecularly defined approach to antigen-specific adoptive transfer therapy of cancer.

Type

Journal article

Journal

Cancer Res

Publication Date

01/05/1999

Volume

59

Pages

2167 - 2173

Keywords

Antigens, Neoplasm, Biotinylation, Cell Line, Cell Separation, Cytotoxicity, Immunologic, Flow Cytometry, Fluorescent Antibody Technique, Indirect, HLA-A2 Antigen, Humans, Immunodominant Epitopes, Immunotherapy, Adoptive, Interleukin-2, Lymphocyte Activation, MART-1 Antigen, Macromolecular Substances, Melanoma, Neoplasm Proteins, Peptide Fragments, Recombinant Fusion Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured